Abivax, a French biotech firm, experienced a dramatic recovery in its stock price after releasing updated data from a late-stage clinical trial for its lead drug, obefazimod, aimed at treating ulcerative colitis.
The stock jumped 25% shortly after the market opened, recovering from a 44% drop earlier in June when initial trial results raised alarms about potential cancer cases among patients receiving the highest dosage. The latest data indicated that the incidence of malignancies was consistent with expected background rates, which helped to alleviate some investor fears.
However, analysts from Jefferies expressed caution, noting that while the update was 'supportive,' concerns about cancer risk and the company's future cash needs could still weigh on investor sentiment.
Additionally, Abivax is viewed as a potential acquisition target, with speculation that several large pharmaceutical companies may be interested in acquiring the company, which adds another layer of interest for investors. This situation highlights the volatility often seen in biotech stocks, particularly those involved in clinical trials